Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA

Zhong Ye, Chun Wang, Shaogui Wan, Zhaomei Mu, Zhenchao Zhang, Maysa M. Abu-Khalaf, Frederick M. Fellin, Daniel P. Silver, Manish Neupane, Rebecca J. Jaslow, Saveri Bhattacharya, Theodore N. Tsangaris, Inna Chervoneva, Adam Berger, Laura Austin, Juan P. Palazzo, Ronald E. Myers, Neha Pancholy, Darayus Toorkey, Kaelan Yao & 10 others Max Krall, Xiuling Li, Xiaobing Chen, Xiuhong Fu, Jinliang Xing, Lifang Hou, Qiang Wei, Bingshan Li, Massimo Cristofanilli, Hushan Yang*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: Both circulating tumour cell (CTC) and total circulating cell-free DNA (ccfDNA) predict cancer patient prognosis. However, no study has explored the prognostic value of the combined use of CTC and ccfDNA. We aimed to investigate individual and joint effects of CTC and ccfDNA on clinical outcomes of metastatic breast cancer (MBC) patients. Methods: We collected 227 blood samples from 117 MBC patients. CTCs were enumerated using the CellSearch System. ccfDNAs were quantified by quantitative real-time polymerase chain reaction and Qubit fluorometer. The individual and joint effects of CTC and ccfDNA levels on patient progression-free survival (PFS) and overall survival (OS) were analysed using Cox proportional hazards models. Results: Compared to patients with <5 CTCs, patients with ≥5 CTCs had a 2.58-fold increased risk of progression and 3.63-fold increased risk of death. High level of ccfDNA was associated with a 2.05-fold increased risk of progression and 3.56-fold increased risk of death. These associations remained significant after adjusting for other important clinical covariates and CTC/ccfDNA levels. CTC and ccfDNA levels had a joint effect on patient outcomes. Compared to patients with low levels of both CTC and ccfDNA, those with high levels of both markers exhibited a >17-fold increased death risk (P < 0.001). Moreover, longitudinal analysis of 132 samples from 22 patients suggested that the inconsistency between CTC level and outcome in some patients could possibly be explained by ccfDNA level. Conclusions: CTC and total ccfDNA levels were individually and jointly associated with PFS and OS in MBC patients.

Original languageEnglish (US)
Pages (from-to)133-143
Number of pages11
JournalEuropean Journal of Cancer
Volume106
DOIs
StatePublished - Jan 1 2019

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
DNA
Disease-Free Survival
Survival
Proportional Hazards Models
Real-Time Polymerase Chain Reaction

Keywords

  • Circulating cell-free DNA (ccfDNA)
  • Circulating tumour cell (CTC)
  • Metastatic breast cancer (MBC)
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ye, Zhong ; Wang, Chun ; Wan, Shaogui ; Mu, Zhaomei ; Zhang, Zhenchao ; Abu-Khalaf, Maysa M. ; Fellin, Frederick M. ; Silver, Daniel P. ; Neupane, Manish ; Jaslow, Rebecca J. ; Bhattacharya, Saveri ; Tsangaris, Theodore N. ; Chervoneva, Inna ; Berger, Adam ; Austin, Laura ; Palazzo, Juan P. ; Myers, Ronald E. ; Pancholy, Neha ; Toorkey, Darayus ; Yao, Kaelan ; Krall, Max ; Li, Xiuling ; Chen, Xiaobing ; Fu, Xiuhong ; Xing, Jinliang ; Hou, Lifang ; Wei, Qiang ; Li, Bingshan ; Cristofanilli, Massimo ; Yang, Hushan. / Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. In: European Journal of Cancer. 2019 ; Vol. 106. pp. 133-143.
@article{43647b13ceda42e782b9d13ce5ea95cc,
title = "Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA",
abstract = "Background: Both circulating tumour cell (CTC) and total circulating cell-free DNA (ccfDNA) predict cancer patient prognosis. However, no study has explored the prognostic value of the combined use of CTC and ccfDNA. We aimed to investigate individual and joint effects of CTC and ccfDNA on clinical outcomes of metastatic breast cancer (MBC) patients. Methods: We collected 227 blood samples from 117 MBC patients. CTCs were enumerated using the CellSearch System. ccfDNAs were quantified by quantitative real-time polymerase chain reaction and Qubit fluorometer. The individual and joint effects of CTC and ccfDNA levels on patient progression-free survival (PFS) and overall survival (OS) were analysed using Cox proportional hazards models. Results: Compared to patients with <5 CTCs, patients with ≥5 CTCs had a 2.58-fold increased risk of progression and 3.63-fold increased risk of death. High level of ccfDNA was associated with a 2.05-fold increased risk of progression and 3.56-fold increased risk of death. These associations remained significant after adjusting for other important clinical covariates and CTC/ccfDNA levels. CTC and ccfDNA levels had a joint effect on patient outcomes. Compared to patients with low levels of both CTC and ccfDNA, those with high levels of both markers exhibited a >17-fold increased death risk (P < 0.001). Moreover, longitudinal analysis of 132 samples from 22 patients suggested that the inconsistency between CTC level and outcome in some patients could possibly be explained by ccfDNA level. Conclusions: CTC and total ccfDNA levels were individually and jointly associated with PFS and OS in MBC patients.",
keywords = "Circulating cell-free DNA (ccfDNA), Circulating tumour cell (CTC), Metastatic breast cancer (MBC), Prognosis",
author = "Zhong Ye and Chun Wang and Shaogui Wan and Zhaomei Mu and Zhenchao Zhang and Abu-Khalaf, {Maysa M.} and Fellin, {Frederick M.} and Silver, {Daniel P.} and Manish Neupane and Jaslow, {Rebecca J.} and Saveri Bhattacharya and Tsangaris, {Theodore N.} and Inna Chervoneva and Adam Berger and Laura Austin and Palazzo, {Juan P.} and Myers, {Ronald E.} and Neha Pancholy and Darayus Toorkey and Kaelan Yao and Max Krall and Xiuling Li and Xiaobing Chen and Xiuhong Fu and Jinliang Xing and Lifang Hou and Qiang Wei and Bingshan Li and Massimo Cristofanilli and Hushan Yang",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2018.10.012",
language = "English (US)",
volume = "106",
pages = "133--143",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

Ye, Z, Wang, C, Wan, S, Mu, Z, Zhang, Z, Abu-Khalaf, MM, Fellin, FM, Silver, DP, Neupane, M, Jaslow, RJ, Bhattacharya, S, Tsangaris, TN, Chervoneva, I, Berger, A, Austin, L, Palazzo, JP, Myers, RE, Pancholy, N, Toorkey, D, Yao, K, Krall, M, Li, X, Chen, X, Fu, X, Xing, J, Hou, L, Wei, Q, Li, B, Cristofanilli, M & Yang, H 2019, 'Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA', European Journal of Cancer, vol. 106, pp. 133-143. https://doi.org/10.1016/j.ejca.2018.10.012

Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. / Ye, Zhong; Wang, Chun; Wan, Shaogui; Mu, Zhaomei; Zhang, Zhenchao; Abu-Khalaf, Maysa M.; Fellin, Frederick M.; Silver, Daniel P.; Neupane, Manish; Jaslow, Rebecca J.; Bhattacharya, Saveri; Tsangaris, Theodore N.; Chervoneva, Inna; Berger, Adam; Austin, Laura; Palazzo, Juan P.; Myers, Ronald E.; Pancholy, Neha; Toorkey, Darayus; Yao, Kaelan; Krall, Max; Li, Xiuling; Chen, Xiaobing; Fu, Xiuhong; Xing, Jinliang; Hou, Lifang; Wei, Qiang; Li, Bingshan; Cristofanilli, Massimo; Yang, Hushan.

In: European Journal of Cancer, Vol. 106, 01.01.2019, p. 133-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA

AU - Ye, Zhong

AU - Wang, Chun

AU - Wan, Shaogui

AU - Mu, Zhaomei

AU - Zhang, Zhenchao

AU - Abu-Khalaf, Maysa M.

AU - Fellin, Frederick M.

AU - Silver, Daniel P.

AU - Neupane, Manish

AU - Jaslow, Rebecca J.

AU - Bhattacharya, Saveri

AU - Tsangaris, Theodore N.

AU - Chervoneva, Inna

AU - Berger, Adam

AU - Austin, Laura

AU - Palazzo, Juan P.

AU - Myers, Ronald E.

AU - Pancholy, Neha

AU - Toorkey, Darayus

AU - Yao, Kaelan

AU - Krall, Max

AU - Li, Xiuling

AU - Chen, Xiaobing

AU - Fu, Xiuhong

AU - Xing, Jinliang

AU - Hou, Lifang

AU - Wei, Qiang

AU - Li, Bingshan

AU - Cristofanilli, Massimo

AU - Yang, Hushan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Both circulating tumour cell (CTC) and total circulating cell-free DNA (ccfDNA) predict cancer patient prognosis. However, no study has explored the prognostic value of the combined use of CTC and ccfDNA. We aimed to investigate individual and joint effects of CTC and ccfDNA on clinical outcomes of metastatic breast cancer (MBC) patients. Methods: We collected 227 blood samples from 117 MBC patients. CTCs were enumerated using the CellSearch System. ccfDNAs were quantified by quantitative real-time polymerase chain reaction and Qubit fluorometer. The individual and joint effects of CTC and ccfDNA levels on patient progression-free survival (PFS) and overall survival (OS) were analysed using Cox proportional hazards models. Results: Compared to patients with <5 CTCs, patients with ≥5 CTCs had a 2.58-fold increased risk of progression and 3.63-fold increased risk of death. High level of ccfDNA was associated with a 2.05-fold increased risk of progression and 3.56-fold increased risk of death. These associations remained significant after adjusting for other important clinical covariates and CTC/ccfDNA levels. CTC and ccfDNA levels had a joint effect on patient outcomes. Compared to patients with low levels of both CTC and ccfDNA, those with high levels of both markers exhibited a >17-fold increased death risk (P < 0.001). Moreover, longitudinal analysis of 132 samples from 22 patients suggested that the inconsistency between CTC level and outcome in some patients could possibly be explained by ccfDNA level. Conclusions: CTC and total ccfDNA levels were individually and jointly associated with PFS and OS in MBC patients.

AB - Background: Both circulating tumour cell (CTC) and total circulating cell-free DNA (ccfDNA) predict cancer patient prognosis. However, no study has explored the prognostic value of the combined use of CTC and ccfDNA. We aimed to investigate individual and joint effects of CTC and ccfDNA on clinical outcomes of metastatic breast cancer (MBC) patients. Methods: We collected 227 blood samples from 117 MBC patients. CTCs were enumerated using the CellSearch System. ccfDNAs were quantified by quantitative real-time polymerase chain reaction and Qubit fluorometer. The individual and joint effects of CTC and ccfDNA levels on patient progression-free survival (PFS) and overall survival (OS) were analysed using Cox proportional hazards models. Results: Compared to patients with <5 CTCs, patients with ≥5 CTCs had a 2.58-fold increased risk of progression and 3.63-fold increased risk of death. High level of ccfDNA was associated with a 2.05-fold increased risk of progression and 3.56-fold increased risk of death. These associations remained significant after adjusting for other important clinical covariates and CTC/ccfDNA levels. CTC and ccfDNA levels had a joint effect on patient outcomes. Compared to patients with low levels of both CTC and ccfDNA, those with high levels of both markers exhibited a >17-fold increased death risk (P < 0.001). Moreover, longitudinal analysis of 132 samples from 22 patients suggested that the inconsistency between CTC level and outcome in some patients could possibly be explained by ccfDNA level. Conclusions: CTC and total ccfDNA levels were individually and jointly associated with PFS and OS in MBC patients.

KW - Circulating cell-free DNA (ccfDNA)

KW - Circulating tumour cell (CTC)

KW - Metastatic breast cancer (MBC)

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85057878734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057878734&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.10.012

DO - 10.1016/j.ejca.2018.10.012

M3 - Article

VL - 106

SP - 133

EP - 143

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -